Table 3.

Incidence of IRAEs during ICI therapy for cases and controls.

	Case, n (%)	Control, n (%)	OR (95% CI)
All grade IRAEs	5 (45.5%)	11 (50.0%)	0.83 (0.2–3.56)
Grades 1 and 2	2 (18.2%)	7 (31.8%)	0.48 (0.08–2.81)
Grade 3 and 4	3 (27.3%)	4 (18.2%)	1.69 (0.31–9.36)
Organ system
Gastroenterological	2 (18.2%)	0 (0.0%)
Musculoskeletal	2 (18.2%)	0 (0.0%)
Neurologic	1 (9.1%)	0 (0.0%)
Respiratory	0 (0.0%)	1 (4.5%)
Cardiac	0 (0.0%)	1 (4.5%)
Endocrine	0 (0.0%)	1 (4.5%)
Dermatologic	0 (0.0%)	1 (4.5%)

IRAEs, immune-related adverse events; OR, odds ratio; CI, confidence interval.

Odds of IRAEs were not statistically significantly different between cases and controls for all grades.